Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Association between vitamin D receptor activator and the risk of infection-related hospitalizations among incident hemodialysis patients: a nested case-control study.

Normand I, Elftouh N, Laurin LP, Ouimet D, Harrak H, Lafrance JP.

Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):261-7. doi: 10.1002/pds.3576. Epub 2014 Jan 27.

PMID:
24470433
2.

Active vitamin D and acute respiratory infections in dialysis patients.

Tsujimoto Y, Tahara H, Shoji T, Emoto M, Koyama H, Ishimura E, Tabata T, Nishizawa Y, Inaba M.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1361-7. doi: 10.2215/CJN.08871010. Epub 2011 May 26.

3.

Ability of vitamin D receptor activator to prevent pulmonary congestion in advanced chronic kidney disease.

Sueta S, Morozumi K, Takeda A, Horike K, Otsuka Y, Shinjo H, Murata M, Kato Y, Goto K, Inaguma D; Aichi cohort study of prognosis in patients newly initiated into dialysis (AICOPP) study group.

Clin Exp Nephrol. 2015 Jun;19(3):371-8. doi: 10.1007/s10157-014-0994-x. Epub 2014 Jun 11.

PMID:
24916005
4.

Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients.

Shoji T, Marubayashi S, Shigematsu T, Iseki K, Tsubakihara Y; Committee of Renal Data Registry; Japanese Society for Dialysis Therapy.

Ther Apher Dial. 2015 Jun;19(3):235-44. doi: 10.1111/1744-9987.12274. Epub 2014 Dec 19.

PMID:
25530222
5.

Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study.

Messa P, Cozzolino M, Brancaccio D, Cannella G, Malberti F, Costanzo AM, di Luzio Paparatti U, Festa V, Gualberti G, Mazzaferro S; FARO Study Group.

BMC Nephrol. 2015 Feb 6;16:11. doi: 10.1186/s12882-015-0006-8.

6.

Outcomes of Infection-Related Hospitalization according to Dialysis Modality.

Laurin LP, Harrak H, Elftouh N, Ouimet D, Vallée M, Lafrance JP.

Clin J Am Soc Nephrol. 2015 May 7;10(5):817-24. doi: 10.2215/CJN.09210914. Epub 2015 Mar 27.

7.

Association between acetylsalicylic acid and the risk of dialysis-related infections or septicemia among incident hemodialysis patients: a nested case-control study.

Harrak H, Normand I, Grinker R, Elftouh N, Laurin LP, Lafrance JP.

BMC Nephrol. 2015 Jul 28;16:115. doi: 10.1186/s12882-015-0112-7.

8.

Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients.

Ogawa T, Kyono A, Sato M, Sugimoto H, Otsuka K, Nitta K.

Clin Exp Nephrol. 2012 Oct;16(5):779-85. doi: 10.1007/s10157-012-0626-2. Epub 2012 Mar 29.

PMID:
22457088
9.

The impact of treatment modality on infection-related hospitalization rates in peritoneal dialysis and hemodialysis patients.

Williams VR, Quinn R, Callery S, Kiss A, Oliver MJ.

Perit Dial Int. 2011 Jul-Aug;31(4):440-9. doi: 10.3747/pdi.2009.00224. Epub 2010 Jul 29.

PMID:
20671104
10.

Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.

Fukagawa M, Fukuma S, Onishi Y, Yamaguchi T, Hasegawa T, Akizawa T, Kurokawa K, Fukuhara S.

Clin J Am Soc Nephrol. 2012 Sep;7(9):1473-80. Epub 2012 Jul 19.

11.

VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.

Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M, LoDeserto C, Pozzato M, Rombolà G, Costanzo AM, di Luzio Paparatti U, Mazzaferro S; FARO Study Group.

Nephrol Dial Transplant. 2012 Sep;27(9):3588-94. Epub 2012 Apr 20.

PMID:
22523119
12.

Association of dialysis modality with risk for infection-related hospitalization: a propensity score-matched cohort analysis.

Lafrance JP, Rahme E, Iqbal S, Elftouh N, Vallée M, Laurin LP, Ouimet D.

Clin J Am Soc Nephrol. 2012 Oct;7(10):1598-605. doi: 10.2215/CJN.00440112. Epub 2012 Aug 16.

13.

Effect of vitamin D receptor activator therapy on vitamin D receptor and osteocalcin expression in circulating endothelial progenitor cells of hemodialysis patients.

Cianciolo G, La Manna G, Della Bella E, Cappuccilli ML, Angelini ML, Dormi A, Capelli I, Laterza C, Costa R, Alviano F, Donati G, Ronco C, Stefoni S.

Blood Purif. 2013;35(1-3):187-95. doi: 10.1159/000347102. Epub 2013 Mar 13.

PMID:
23485859
14.

Lower serum sodium level predicts higher risk of infection-related hospitalization in maintenance hemodialysis patients: an observational cohort study.

Mandai S, Kuwahara M, Kasagi Y, Kusaka K, Tanaka T, Shikuma S, Akita W, Sasaki S.

BMC Nephrol. 2013 Dec 19;14:276. doi: 10.1186/1471-2369-14-276.

15.

Predialysis Vitamin D Receptor Activator Treatment and Cardiovascular Events after Dialysis Initiation: A Multicenter Observational Study.

Inaguma D, Tanaka A, Shinjo H, Kato A, Murata M; Aichi cohort study of prognosis in patients newly initiated into dialysis (AICOPP) group.

Nephron. 2016;133(1):35-43. doi: 10.1159/000445507. Epub 2016 Apr 8.

PMID:
27054694
16.

Comparison of oral versus intravenous vitamin D receptor activator in reducing infection-related mortality in hemodialysis patients: the Q-Cohort Study.

Tanaka S, Ninomiya T, Taniguchi M, Fujisaki K, Tokumoto M, Hirakata H, Ooboshi H, Kitazono T, Tsuruya K.

Nephrol Dial Transplant. 2016 Jul;31(7):1152-60. doi: 10.1093/ndt/gfw205. Epub 2016 May 27.

PMID:
27235424
17.

Hospital-acquired infections among chronic hemodialysis patients.

D'Agata EM, Mount DB, Thayer V, Schaffner W.

Am J Kidney Dis. 2000 Jun;35(6):1083-8.

PMID:
10845821
18.

Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients.

Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S; Canadian Nosocomial Infection Surveillance Program; Canadian Hospital Epidemiology Committee.

Am J Infect Control. 2004 May;32(3):155-60.

PMID:
15153927
19.

Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism.

Tanaka M, Tokunaga K, Komaba H, Itoh K, Matsushita K, Watanabe H, Kadowaki D, Maruyama T, Otagiri M, Fukagawa M.

Ther Apher Dial. 2011 Apr;15(2):161-8. doi: 10.1111/j.1744-9987.2010.00890.x. Epub 2011 Jan 25.

PMID:
21426509
20.

Association of oral calcitriol with improved survival in nondialyzed CKD.

Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B.

J Am Soc Nephrol. 2008 Aug;19(8):1613-9. doi: 10.1681/ASN.2007111164. Epub 2008 May 7.

Supplemental Content

Support Center